Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: Evolution in the definition and management of primary nonresponse

Inflammatory Bowel Diseases

Volumn 21, Issue 1, 2015, Pages 182-197

  Papamichael, Konstantinos ^a   Gils, Ann ^a   Rutgeerts, Paul ^a   Levesque, Barrett G ^b,c   Vermeire, Séverine ^a   Sandborn, William J ^b,c   Vande Casteele, Niels ^a,b,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Anti TNF; Immunogenicity; Inflammatory bowel disease; Primary nonresponse; Therapeutic drug monitoring

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY BLOOD LEVEL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; DRUG TREATMENT FAILURE; HUMAN; INFLAMMATORY BOWEL DISEASE; PATIENT CARE; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; TREATMENT OUTCOME; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; DISEASE MANAGEMENT; INFLAMMATORY BOWEL DISEASES; REMISSION;

ANTIBODIES, MONOCLONAL; DISEASE MANAGEMENT; DRUG MONITORING; HUMANS; INFLAMMATORY BOWEL DISEASES; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925776153     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000202     Document Type: Review

References (189)

1. Baumgart DC, SandbornWJ. Crohn's disease. Lancet. 2012;380:1590-1605.
2. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012; 380:1606-1619.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
4. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
6. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010;8:688-695.
7. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265.
8. Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109.
9. Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95.
10. Papamichael K, Archavlis E, Lariou C, et al. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohns Colitis. 2012;6:924-931.
11. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355-366.
12. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulising Crohn's disease. N Engl J Med. 2004;350:876-885.
13. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009;58:492-500.
14. Billiet T, Bruyn M, Ballet V, et al. Prediction of primary response to infliximab in Crohn's disease: a matrix-based prediction model. Gastroenterology. 2014;146:S-239.
15. Papamichael K, Gazouli M, Tsirogianni A, et al. Primary non response to infliximab in patients with inflammatory bowel disease. Gastroenterology. 2014;146:S-457.
16. Zorzi F, Zuzzi S, Onali S, et al. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Aliment Pharmacol Ther. 2012;35:1397-1407.
17. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
18. Russo EA, Harris AW, Campbell S, et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther. 2009;29:308-314.
19. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219-225.
20. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
21. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
22. Sprakes MB, Hamlin PJ, Warren L, et al. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: a single centre experience. J Crohns Colitis. 2011;5:324-331.
23. Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis. 2013;7:154-160.
24. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
25. Swoger JM, Loftus EV Jr, Tremaine WJ, et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010;16:1912-1921.
26. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut. 2011;60: 780-787.
27. Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283-294.
28. McDermott E, Murphy S, Keegan D, et al, Doherty G Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis. 2013;7:150-153.
29. Taxonera C, Estellés J, Fernández-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33:340-348.
30. García-Bosch O, Gisbert JP, Cañas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis. 2013;7:717-722.
31. Schreiber S, Khaliq-Kareem M, Lauwrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357:239-250.
32. Sandborn WJ, Feagan BG, Stoinov S, et al; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
33. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011;9:670-678.
34. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology. 2004;126:1257-1269.
35. Schreiber S, Rutgeerts P, Fedorak RN, et al; CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818.
36. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574-1582.
37. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
38. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535-542.
39. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013;145:149-157.
40. Khanna R, D'Haens GR, Feagan BG, et al. Patient reported outcome measures derived from the Crohn's disease activity index: correlation between PRO2 and PRO3 scores and CDAI defined clinical thresholds. Gastroenterology. 2014;146:S-226.
41. Bendtzen K. Anti-TNF-a biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy. 2012;4:1167-1179.
42. Leal RF, Planell N, Kajekar R, et al. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFa therapy. Gut. 2014 [Epub ahead of print].
43. Echarri A, Ferreiro R, Fraga-Iriso R, et al. Drug trough levels and primary nonresponse to antiTNF therapy in moderate-severe crohn disease. Results of the Optimiza study. Gastroenterology. 2014;146:S-247.
44. Brandse JF, van der Kleij D, Wolbink GJ, et al. The pharmacokinetics of infliximab induction therapy in patients with moderate to severe ulcerative colitis. Gastroenterology. 2014;146:S-134.
45. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor-a inhibitor infliximab. Arthritis Rheum. 2006;54:3782-3789.
46. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987-995.
47. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11:243-255.
48. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
49. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
50. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol. 2011;46:310-318.
51. Steenholdt C, Al-khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2209-2217.
52. Ungar B, Chowers Y, Yavzori M, et al; on behalf of ABIRISK Consortium. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258-1264.
53. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523-529.
54. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739-1745.
55. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol. 2012;47:136-143.
56. Imaeda H, Bamba S, Takahashi K, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol. 2014;49: 674-682.
57. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962-971.
58. Maser EA, Villela R, Silverberg MS, et al Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
59. Yamada A, Sono K, Hosoe N, et al. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis. 2010;16:1898-1904.
60. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013;7:736-743.
61. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retro-spective analysis of the ACCENT I trial. Gut. [published online ahead of print March 4, 2014]. doi: 10.1136/gutjnl-2012-304094.
62. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:80-84.
63. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013;19:1112-1122.
64. Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568-576.
65. Bruining DH, Sandborn WJ. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:395-399.
66. Vermeire S, Van Assche G, Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol. 2010;16: 2609-2615.
67. Arias MT, Van de Casteele N, Drobne D, et al. Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis. J Crohns Colitis. 2012;6:S5.
68. Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70: 1208-1215.
69. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pre-treatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:704-707.
70. Reinisch W, Feagan BG, Rutgeerts PJ, et al. 566 Infliximab concentration and clinical outcome in patients with ulcerative colitis. Gastroenterology. 2012;142:S-114.
71. Yarur AJ, Abreu MT, Deshpande AR, et al. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol. 2014;20:3475-3484.
72. Nattiv R, Wojcicki JM, Garnett EA, et al. High-dose infliximab for treatment of pediatric ulcerative colitis: a survey of clinical practice. World J Gastroenterol. 2012;18:1229-1234.
73. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-a antibodies. Scand J Gastroenterol. 2009;44:774-781.
74. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
75. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2012;6:991-1030.
76. de Silva PS, Nguyen DD, Sauk J, et al. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:459-466.
77. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31: 92-101.
78. Chaparro M, Andreu M, Barreiro-de Acosta M, et al. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol. 2012;18:5219-5224.
79. Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919-927.
80. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013;11:654-666.
81. D'Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212.
82. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
83. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442.
84. Ha C, Ullman TA, Siegel CA, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10:1002-1007.
85. Dubinsky MC, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1357-1366.
86. Keizer RJ, Huitema ADR, Schellens JHM, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 48:493-507.
87. Tabrizi M, Tseng CM, Roskos L. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81-88.
88. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:1079-1087.
89. Moroi R, Endo K, Kinouchi Y, et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics. 2013;65:265-271.
90. Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011; 33:946-964.
91. Kevans D, Murthy S, Iaccono A, et al. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology. 2012;142: S384-S385.
92. Mostafa NM, Eckert D, Pradhan RS, et al. Exposure-efficacy relationship (ER) for adalimumab during induction phase of treatment of adult patients with moderate to severe ulcerative colitis (UC). United Eur Gastroenterol J. 2013;1:A221-A222.
93. Magro F, Rodrigues-Pinto E, Santos-Antunes J, et al. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2014;8:129-136.
94. Hibi T, Sakuraba A, Watanabe M, et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. J Gastroenterol. 2014;49:254-262.
95. Yarur AJ, Deshpande AR, Sussman DA, et al. Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. Gastroenterology. 2012;144:S-774.
96. Velayos FS, Sheibani S, Lockton S, et al. Prevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patients. Gastroenterology. 2012;144:S-91.
97. Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48:297-308.
98. Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184:1968-1976.
99. Mori S, Ueki Y. Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab. Mod Rheumatol. 2011;21:628-636.
100. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-924.
101. Krintel SB, Grunert VP, Hetland ML, et al. The frequency of antiinfliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology. 2013;52:1245-1253.
102. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013; 108:40-47.
103. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
104. Bar-Yoseph H, Chowers Y, Ben-Horin S, et al. Infliximab is more immunogenic and reaches lower trough levels in ulcerative colitis patients compared to Crohn's disease patients. Gastroenterology. 2013; 144:S780.
105. Van Moerkercke W, Cleynen I, Compernolle G, et al. Trough levels of infliximab in a cohort of primary non-responders. Gut. 2009; 58:A70.
106. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944-948.
107. Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor a expression in the synovium. Ann Rheum Dis. 2008;67:1139-1144.
108. Brandse JF, Wildenberg ME, de Bruyn JR, et al. Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease. J Crohns Colitis. 2013;7:S210.
109. Ebert EC, Das KM, Mehta V, et al. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies. Clin Exp Immunol. 2008;154:325-331.
110. Steenholdt C, Palarasah Y, Bendtzen K, et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1172-1183.
111. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36:765-771.
112. Gils A, Vande Casteele N, Poppe R, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit. 2014;36:669-673.
113. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382:177-188.
114. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol. 2014;49:100-109.
115. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711-715.
116. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis. 2012;18:1628-1633.
117. Patton A, Mullenix MC, Swanson SJ, et al. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods. 2005;304: 189-195.
118. Van Schouwenburg PA, Bartelds GM, Hart MH, et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362:82-88.
119. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2004;19: 511-519.
120. Arias MT, Cleynen I, Karolien C, et al. The role of Fc Gamma Receptor (FcgR) mutations in the response to infliximab in Inflammatory Bowel Disease. Gastroenterology. 2011;140:S1.
121. Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther. 2005;22:613-626.
122. Lopez-Hernández R, Valdés M, Campillo JA, et al. Genetic polymorphisms of tumour necrosis factor alpha (TNF-a) promoter gene and response to TNF-a inhibitors in Spanish patients with inflammatory bowel disease. Int J Immunogenet. 2014;41:63-68.
123. Thomas D, Gazouli M, Karantanos T, et al. Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease. World J Gastroenterol. 2014;20:3609-3614.
124. Hlavaty T, Ferrante M, Henckaerts L, et al. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis. 2007;13:372-379.
125. Dideberg V, Théâtre E, Farnir F, et al. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics. 2006;16: 727-734.
126. Pierik M, Vermeire S, Steen KV, et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther. 2004; 20:303-310.
127. Matsukura H, Ikeda S, Yoshimura N, et al. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. Aliment Pharmacol Ther. 2008;27:765-770.
128. Billiet T, Cleynen I, Ballet V, et al. Primary response to infliximab in Crohn's disease is associated with the Tnfrsf1a Rs1800693 gene polymorphism. Gastroenterology. 2013;144:S467-S468.
129. Steenholdt C, Enevold C, Ainsworth MA, et al. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2012;36:650-659.
130. Gutiérrez A, Scharl M, Sempere L, et al. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut. 2014;63: 272-280.
131. Urcelay E, Mendoza JL, Martinez A, et al. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. World J Gastroenterol. 2005;11:1187-1192.
132. Jürgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105: 1811-1819.
133. Vermeire S, Louis E, Carbonez A, et al; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002;97:2357-2363.
134. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007; 13:123-128.
135. Laharie D, Salzmann M, Boubekeur H, et al. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol. 2005;29: 145-149.
136. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003;17:1451-1457.
137. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002; 123:707-713.
138. Lee KM, Jeen YT, Cho JY, et al; IBD study Group of Korean Association for the Study of Intestinal Diseases. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol. 2013;28: 1829-1833.
139. Orlando A, Colombo E, Kohn A, et al. Italian Multicentric Study Group on Infliximab. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian Multicentric Open Study. Dig Liver Dis. 2005; 37:577-583.
140. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn's disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818-824.
141. Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:421-427.
142. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol. 2002; 97:2350-2356.
143. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105:2617-2625.
144. Meuwis MA, Fillet M, Lutteri L, et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem. 2008;41:960-967.
145. Bouchaud G, Mortier E, Flamant M, et al. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease. Gastroenterology. 2010;138:2378-2387.
146. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009; 58:1612-1619.
147. Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010;16:2090-2098.
148. Olsen T, Goll R, Cui G, et al. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine. 2009;46:222-227.
149. Wojtal KA, Rogler G, Scharl M, et al. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS ONE. 2012;7: e43361.
150. Rismo R, Olsen T, Cui G, et al. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol. 2012;47:538-547.
151. Siegel CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of Crohn's disease. Ther Adv Gastroenterol. 2009; 2:244-251.
152. Papamichael K, Gazouli M, Karakoidas CH, et al. Association of TNF and FcgRIIIA gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients. Ann Gastroenterol. 2011;24:35-40.
153. Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics. 2006;16:911-914.
154. González S, Rodrigo L, Martínez-Borra J, et al. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol. 2003;98:1101-1106.
155. Schmidt C, Giese T, Hermann E, et al. Predictive value of mucosal TNFalpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis. 2007;13:65-70.
156. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Pharmacol. 2009;65:1211-1228.
157. Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16:378.
158. Magdelaine-Beuzelin C, Vermeire S, Goodall M, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics. 2009;19: 383-387.
159. Bartelds GM, Wijsman EM, Nurmohamed MT, et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 2009;60:2541-2542.
160. Billiet T, Vande Casteele N, Cleynen I, et al. HLA-DRB1 and the development of antibodies to infliximab in inflammatory bowel disease. United Eur Gastroenterol J. 2013;1:A361.
161. Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. J Clin Pharm. [published online ahead of print].
162. Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2118-2124.
163. Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther. 2012;35:335-341.
164. Bhalme M, Sharma A, Keld R, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease? Eur J Gastroenterol Hepatol. 2013;25:543-549.
165. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut. 2012;61:78-85.
166. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008; 134:1861-1868.
167. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11: 444-447.
168. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology. 2014;146: 681-688.e1.
169. Mould D, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. Biodrugs. 2010;24:23-39.
170. Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol. 2011;23:1100-1110.
171. Sandborn WJ, Feagan BG, Rutgeerts P, et al; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721.
172. Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384:309-318.
173. Kiss LS, Szamosi T, Molnar T, et al; Hungarian IBD Study Group. Early clinical remission and normalization of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2011; 34:911-922.
174. Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther. 2008; 27:308-315.
175. Swaminath A, Ullman T, Rosen M, et al. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients. Aliment Pharmacol Ther. 2009; 29:273-278.
176. Lofberg R, Louis E, Reinisch W. Adalimumab effectiveness in TNF-antagonist-naive patients and in infliximab nonresponders with Crohn's disease: results from the CARE study. Am J Gastroenterol. 2008;103:1069.
177. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32: 1228-1239.
178. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther. 2009;29:527-534.
179. Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn's disease-safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther. 2007;25:787-796.
180. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13: 1323-1332.
181. Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91:635-646.
182. Danese S, Mocciaro F, Guidi L, et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life randomized experience of compassionate use. Inflamm Bowel Dis. 2008;14:1168-1170.
183. Jamnitski A, Bartelds GM, Nurmohamed MT. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70: 284-288.
184. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105: 1133-1139.
185. Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
186. Sandborn WJ, Gasink C, Gao LL, et al; CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519-1528.
187. Sandborn WJ, Ghosh S, Panes J, et al. Study A3921063 Investigators Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616-624.
188. Atreya R, Neumann H, Neufert C, et al. In vivo molecular imaging using fluorescent anti-TNF antibodies and confocal laser endomicroscopy predicts response to anti-TNF therapy in Crohn's disease. Gastroenterology. 2013;144:S-85-S-86.
189. Vande Casteele N, Gils A, Ballet V, et al. OP001 randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: Final results of the TAXIT study. United Eur Gastroenterol J. 2013;1:A1.